Fractyl Stock

fractyl.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $286.48MM

Fractyl ais a biotechnology company looking to bring curative therapies to the large populations of patients with metabolic disease.

Register for Details

For more details on financing and valuation for Fractyl, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Fractyl.

Register Today

Team

Management Team

Jay Caplan
President, Board Member & Co-Founder
Harith Rajagopalan Ph.D
Co-Founder, Chief Executive Officer and Board Member
Diane Marcou
Chief Financial Officer
Lisa Davidson
Chief Financial Officer
David Maggs
Chief Medical Officer

Board Members

Ajay Royan
Mithril Capital Management
Hemant Taneja
General Catalyst
William Bradley
Brian Dovey
Domain Associates
Christopher Gabrieli MD
Bessemer Venture Partners
Jay Caplan
Stanley Lapidus
Allan Will
Harith Rajagopalan Ph.D
John Amatruda

Other companies like Fractyl in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Fractyl Completes $44M Series D Financing |FinSMEs
Fractyl Laboratories Inc., a Lexington, Mass.-based developer of minimally invasive procedural therapy that can reverse metabolic diseases, completed a $44m Series D financing. The round was led by an undisclosed new investor, joined by new investors GV, True Ventures, and the IDO Fund and returning investors General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital …
Updated on: Sep 24, 2023